Morgan Stanley Maintains Overweight on Biohaven, Lowers Price Target to $18

Benzinga Newsdesk www.benzinga.com Negative 80.8%

Neg 80.8% Neu 0% Pos 0%

Morgan Stanley analyst Terence Flynn maintains Biohaven (NYSE:BHVN) with a Overweight and lowers the price target from $21 to $18.